Advanced Aortic Disease

Our multidisciplinary team uses state-of-the-art approaches to shape the future of complex aortic disease care.

Transforming treatment for advanced aortic disease

2025 Outcomes

Baylor Scott & White The Heart Hospital offers a comprehensive care model designed by a specialized team dedicated to innovative treatments for complex aortic diseases. Our aortic team includes geneticists, interventional cardiologists, vascular surgeons, radiologists and cardiothoracic surgeons.

In addition to complex aortic valve repairs, we offer advanced treatment options, including minimally invasive repairs, endovascular grafts, robotic surgery and hybrid surgical approaches, for conditions affecting the aortic root, thoracic aorta and abdominal aorta. Our multidisciplinary clinics continually expand services to offer patients personalized treatment options, which often include less invasive procedures and opportunities to participate in clinical trials.

TOTAL VOLUMES

ROSS:

26

BENTALL HOMOGRAFT:

6

ROOT-SPARING (DAVID/YACOUB):

44

BENTALL BIO PROSTHETIC:

65

BENTALL MECHANICAL:

19

ROOT RECONSTRUCTION:

20

Root-sparing procedures saw 76% growth from FY 2023 to current. Ross, Bentall Bio Prosthetic, Bentall Homograft, Bentall Mechanical and Root Sparing (David/Yacoub) had a 0% stroke rate.

Rolling 12 months from March 2024-Feb. 2025

ROSS PRECEDURE VOLUME

30

20

10

0

FY22

0

FY23

0

FY24

0

58% growth between FY 2023 and FY 2024

22 cases in FY 2025 through March

0% mortality in renal failure and stroke in the last three years

ENDO VS. OPEN

OPEN:

83%

ENDO:

17%

OVERALL THORACIC AORTIC PROCEDURE VOLUME

400

350

300

250

150

100

50

0

FY22

0

FY23

0

FY24

0

FY25

(APRIL 24 – MARCH 25)

0

ANEURYSM, DISSECTION AND OTHER

ANEURYSM:

254

DISSECTION:

76

OTHER:

45

TOTAL:

375

ELECTIVE ANEURYSM:

1.3% stroke | 1.7% renal failure | 1.7% mortality

TEVAR

81 procedures from April 2024-March 2025 with positive outcomes based on STS and VQI registry data

0%

Strokes | Mortality | Spinal ischemia

Re-intervention related to the procedure

Innovations

  • Our team has made significant innovations in the development of branched thoracic endovascular aneurysm repair (TEVAR) grafts and stent TEVAR procedures for the ascending aorta.
  • We are top enrollers in the Gore PIVOTAL, PERSEVERE and ARISE EFS trials, which have already begun to revolutionize patient care and will continue to do so in the future. We are proud to be at the forefront of these advancements.
  • Our team will participate in the upcoming Fenestrated TREO trial: A Prospective, Multicenter, Non-Blinded, Non-Randomized Pivotal Study of the Fenestrated TREO Stent-Graft System in Subjects with Abdominal Aortic Aneurysms Requiring a Fenestrated Graft and Suitable for Endovascular Repair.

Quality awards 2025

Achievements placing us among the elite

Previous

Next